Navigation Links
CuraGen to Present CR011-vcMMAE Data at ASCO
Date:5/28/2009

tive" or "basal-like" breast cancer have limited treatment options and poorer outcomes. Therefore, a significant unmet need remains for novel therapeutic approaches for patients with locally advanced and metastatic breast cancer who have failed other therapies.

About Melanoma

According to the American Cancer Society, it is expected that approximately 60,000 new cases of melanoma will be diagnosed, including nearly 11,000 patients diagnosed with Stage III or Stage IV disease, and an estimated 8,000 people in the U.S. will die of the disease during 2009. The prognosis for patients with advanced melanoma is poor, and studies have shown that the median survival is less than nine months.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a clinical-stage biopharmaceutical company developing promising approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to CuraGen's development program for CR011-vcMMAE, including CuraGen's ability to advance CR011-vcMMAE through Phase II clinical trials for melanoma and metastatic breast cancer, to explore additional doses and schedules of this antibody-drug conjugate, and to explore the potential of CR011-vcMMAE in a patient population in need of new therapies may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by termin
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... The spinal column is one of the most ... to and from the brain through the column control many ... or ailment here can be life altering, and leave the ... over their body. Though back injury and disease can have ... more options available to make things better than ever before. ...
(Date:8/21/2014)... - The Canadian Epilepsy Alliance (CEA) is thrilled to announce ... children about the most common neurological disorder in ... comic series tells a fictional story based on the experiences ... with epilepsy. "Despite the fact that epilepsy ... misinformation and lack of awareness out there," says Gail ...
(Date:8/21/2014)... HAMBURG, Germany , Aug. 21, 2014  IBM ... with Deutsches Elektronen-Synchrotron ( DESY ), a leading national ... speed up management and storage of massive volumes of ... architecture based on IBM software defined technology can ... at peak performance and help scientists worldwide gain faster ...
Breaking Medicine Technology:Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced non-small ... progression free survival (PFS) in epidermal growth factor ... treated Asian patients. Also, BIM deletion independently predicts ... The BIM protein can activate the programmed cell ... cells. BIM deletion has been detected in 12.8% ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Dr. Sen and Dr. Samantha Pearson to help ... contacts, and avoid corrective vision surgery by instead improving ... Michaels, prompting an investigative review. , “There’s a ... of dollars in revenue each year—it’s because people just ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Dayton Children's Hospital ... tower as part of a $141 million campus renewal. ... care tower were unveiled to the public. , The ... plan that will create a campus that meets the needs ... These new care spaces will embody Dayton Children’s unique patient ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... Strength and Conditioning Coach Greg Brittenham Rally Students to Get ... Fit Grant NEW YORK, March 19 New York Knicks ... Brittenham are rallying New York City teens to get teenagers ... campaign called Get Fit By Finals . The ...
... Lawsuit Alleges that Drywall Emits Toxins Harmful to Humans ... Jason and Melissa Harrell recently filed a class ... of themselves and other homeowners who purchased defective homes. ... new home, and those of their neighbors, emits destructive ...
... Va., March 19 Together Rx Access(R), a prescription ... pharmaceutical companies, announced today that it has expanded the ... individuals and families save on the medicines they need ... the new income levels, nearly 90 percent of uninsured ...
... of Anesthesiologists, Action vs. RhetoricCORONA DEL MAR, Calif., March ... very fair odds. Yet, that,s exactly what the foremost ... set the stage for last week when he responded ... press release in which they claimed to be in ...
... by the American Society for Aesthetic Plastic Surgery, the number of cosmetic ... this sharp decline nationally, the flow of patients at the Center for ... , ... Annandale VA (Vocus) March 19, 2009 -- The ASAPS data ...
... been waiting on for the past four years to prove the deposition ... ... March 19, 2009 -- Most ENT,s and physicians have prescribed Sinus ... a clinical study done on the amount of medication deposited and penetrated ...
Cached Medicine News:Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 3Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 4Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 5Health News:Class Action Filed Against South Florida Developer and Supplier of Defective Chinese Drywall 2Health News:Class Action Filed Against South Florida Developer and Supplier of Defective Chinese Drywall 3Health News:Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times 2Health News:Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times 3Health News:Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times 4Health News:Dr. Barry Friedberg comments on David vs. Goliath: Who's Really in the Pursuit of Patient Safety & Satisfaction? 2Health News:The Center for Plastic Surgery in Washington, DC Survives the Economy Despite Nationwide Data Reported by ASAPS 2Health News:New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics 2Health News:New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics 3Health News:New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics 4
Immersion Oil, 150 cs...
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
Immersion oil for microscopy...
... Immersion Oil Type DF is the ... for fluorescence microscopy and it also ... Oil Type FF has virtually zero ... worldwide immersion oil of choice when ...
Medicine Products: